BRAF and NRAS mutations may be risk factorsfor recurrence and shorter survival in conjunctival melanoma, which wouldmake these patients candidates for targeted therapies and comprehensive andindividualized follow-up. Here, BRAF is linked to malignant conjunctival melanoma.